Development and validation of a HPTLC method for analysis of Sunitinib malate
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Pharmaceutical Sciences |
Texto Completo: | https://www.revistas.usp.br/bjps/article/view/128375 |
Resumo: | A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity. |
id |
USP-31_98c15e69364842c26abbd270e3f378c0 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/128375 |
network_acronym_str |
USP-31 |
network_name_str |
Brazilian Journal of Pharmaceutical Sciences |
repository_id_str |
|
spelling |
Development and validation of a HPTLC method for analysis of Sunitinib malate A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity. Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/12837510.1590/s1984-82502016000400003Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 4 (2016); 595-601Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 4 (2016); 595-601Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 4 (2016); 595-6012175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/128375/125246Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessHajmalek, MonirehGoudarzi, MasoumehGhaffari, SolmazAttar, HosseinMazlaghan, Mehrnoosh Ghanbari2017-03-16T18:09:44Zoai:revistas.usp.br:article/128375Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2017-03-16T18:09:44Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
title |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
spellingShingle |
Development and validation of a HPTLC method for analysis of Sunitinib malate Hajmalek, Monireh |
title_short |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
title_full |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
title_fullStr |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
title_full_unstemmed |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
title_sort |
Development and validation of a HPTLC method for analysis of Sunitinib malate |
author |
Hajmalek, Monireh |
author_facet |
Hajmalek, Monireh Goudarzi, Masoumeh Ghaffari, Solmaz Attar, Hossein Mazlaghan, Mehrnoosh Ghanbari |
author_role |
author |
author2 |
Goudarzi, Masoumeh Ghaffari, Solmaz Attar, Hossein Mazlaghan, Mehrnoosh Ghanbari |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Hajmalek, Monireh Goudarzi, Masoumeh Ghaffari, Solmaz Attar, Hossein Mazlaghan, Mehrnoosh Ghanbari |
description |
A simple high performance thin layer chromatography (HPTLC) has been developed and validated for determination of sunitinib malate and possible impurities. The samples were applied in forms of bands on an aluminum TLC plate pre-coated with silica gel and were separated using dichloromethane: methanol: toluene: ammonia solution as the mobile phase. Sunitinib malate was thoroughly separated from impurities including E-isomer, sunitinib N-oxide and impurity B with a retention factor (RF) of 0.35±0.02. Quantitative analysis of sunitinib was carried out using a mobile phase consisting of dichloromethane:methanol:ammonia solution, RF value was 0.53±0.02 for Z isomer. Detection was performed densitometrically in absorbance mode at 430 nm. This method was found to produce sharp, symmetrical, and well resolved peaks. Linear relationship with the coefficients of determination >; 0.99 was achieved over the concentration range of 27.34 to 437.5 ng/spot. This method provides robust, replicable and accurate results with acceptable sensitivity. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/128375 10.1590/s1984-82502016000400003 |
url |
https://www.revistas.usp.br/bjps/article/view/128375 |
identifier_str_mv |
10.1590/s1984-82502016000400003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/bjps/article/view/128375/125246 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso) |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
publisher.none.fl_str_mv |
Universidade de São Paulo. Faculdade de Ciências Farmacêuticas |
dc.source.none.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences; Vol. 52 Núm. 4 (2016); 595-601 Brazilian Journal of Pharmaceutical Sciences; v. 52 n. 4 (2016); 595-601 Brazilian Journal of Pharmaceutical Sciences; Vol. 52 No. 4 (2016); 595-601 2175-9790 1984-8250 reponame:Brazilian Journal of Pharmaceutical Sciences instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Brazilian Journal of Pharmaceutical Sciences |
collection |
Brazilian Journal of Pharmaceutical Sciences |
repository.name.fl_str_mv |
Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
bjps@usp.br||elizabeth.igne@gmail.com |
_version_ |
1800222912855146496 |